Description
Retatrutide is an experimental weight loss and diabetes drug developed by Eli Lilly. It’s a triple hormone receptor agonist, meaning it activates three types of receptors in the body:
1.GLP-1 receptor (Glucagon-Like Peptide-1)
2.GIP receptor (Glucose-Dependent Insulinotropic Polypeptide)
3.Glucagon receptor
This triple action is designed to enhance effects on appetite suppression, metabolism, and blood sugar control, potentially making it more effective than existing drugs like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound), which target only one or two of those receptors.
Key potential benefits:
•Significant weight loss (in early trials, up to ~24% average body weight reduction in some groups)
•Improved glucose control in people with type 2 diabetes
•Long-lasting effects due to once-weekly dosing
As of mid-2024, it was still in clinical trials and not yet FDA-approved. If approved, it could represent a major advancement in obesity and diabetes treatment.
Reviews
There are no reviews yet.